ArticleJournal of neuro-oncology2026
The predictive value of serum neurofilament light chain combined with inflammatory biomarkers for post-surgical epilepsy after brain tumor resection: a retrospective diagnostic study.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundPost-surgical epilepsy (PSE) is a common and debilitating complication after brain tumor resection, impairing recovery and quality of life. Serum neurofilament light chain (NfL) and inflammatory cytokines are emerging biomarkers of neuro-axonal injury and neuroinflammation, yet their combined predictive value for PSE remains underexplored. MATERIALS AND
methodsThis single-center retrospective diagnostic study enrolled 158 adults undergoing first-time brain tumor resection (2020–2024). Serum levels of NfL, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP) were measured preoperatively and on postoperative days 1, 3, and 7. The primary outcome was PSE occurrence within 3 months, diagnosed per International League Against Epilepsy (ILAE) criteria. Independent predictors were identified via multivariable logistic regression, and diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis.
resultsForty-two patients (26.6%) developed PSE. The PSE group exhibited significantly higher serum NfL, IL-6, TNF-α, and CRP levels on postoperative day 3 (all P < 0.01). In multivariable analysis, elevated day-3 NfL (adjusted odds ratio [aOR] = 3.42, 95% confidence interval [CI]: 1.83–6.38) and IL-6 (aOR = 2.75, 95% CI: 1.50–5.05) were independent predictors of PSE. The combination model (NfL + IL-6) demonstrated superior diagnostic accuracy (area under the curve [AUC] = 0.86, 95% CI: 0.80–0.92) compared to single biomarkers.
conclusionsThe combination of serum NfL and IL-6, measured early after surgery, effectively predicts PSE risk following brain tumor resection. This biomarker panel may facilitate early identification of high-risk patients for targeted monitoring and prophylactic intervention. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
41840305What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.